Article

Sydney Morning Herald on 2020-11-04 20:08

Biogen shares soar as FDA reviewers support Alzheimer's drug

Biogen shares soared as much as 47 per cent on Wall Street as FDA reviewers said the company's experimental Alzheimer's disease therapy appears effective.

Related news

WAlzheimer's drug from Biogen, partner receives FDA approval wraltechwire.com
Cambridge , Japan
Biogen cutting cost of Alzheimer's drug Arkansas Online
Japan , Cambridge
Denali shares soar on potential $2.4 billion Parkinson's, Alzheimer's deal with Biogen bizjournals.com
Denali Borough
MBiogen talks up approval plans for controversial Alzheimer's drug as it nears FDA decision marketwatch.com
Japan , Switzerland , Canada , Brazil , Australia
FDA remains upbeat on Alzheimer's drug nwaonline.com
Wall Street , Cambridge
FDA calls for investigation of Biogen Alzheimer's drug approval bizjournals.com
BA Crucial FDA Hearing Looms for Biogen Alzheimer’s Drug barrons.com
Wall Street
MBiogen shares down 9% after Alzheimer's trial results marketwatch.com
Wall Street
Biogen cuts the price tag on its Alzheimer's drug in half - Mon, 20 Dec 2021 PST apnews.com
Massachusetts , Cambridge , Japan
Change at the top for Biogen after Alzheimer's drug flops - Tue, 03 May 2022 PST apnews.com
Europe , Wall Street , Cambridge
Panels find FDA, Biogen rushed Alzheimer’s drug Arkansas Online
Philadelphia , Cambridge
Biogen reanalyzes studies, presses ahead on Alzheimer's drug lasvegassun.com
Indianapolis , Wall Street , Mayo Clinic , United States , Japan
BBiogen Stock Jumps on FDA Approval barrons.com
Wall Street , Mount Sinai , Unmet
MBiogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK4 min marketwatch.com
BA Third Expert Quits FDA Panel Over Approval of Biogen Alzheimer's Drug 2 min barrons.com
MBiogen Alzheimer's drug appears to have setback as FDA advisers recommend not to approve marketwatch.com
Biogen, Eisai to push for fast FDA approval for second Alzheimer's drug bizjournals.com